Gsk (GLAXF) Non-Current Assets (2009 - 2026)

Gsk's Non-Current Assets history runs 18 years deep, the most recent figure standing at $60.8 billion for Q1 2026.

• In Q1 2026, Non-Current Assets rose 13.29% year-over-year to $60.8 billion; the TTM figure through Mar 2026 stood at $60.8 billion (up 13.29% YoY), while the FY2025 annual figure was $57.5 billion, up 5.92% from the prior year.
• Non-Current Assets was $60.8 billion for Q1 2026 at Gsk, up from $58.0 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $60.8 billion in Q1 2026 to a low of $39.9 billion in Q1 2022.
• Historically, Non-Current Assets has averaged $51.4 billion across 5 years, with a median of $52.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets tumbled 51.43% in 2022, then climbed 18.48% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $46.2 billion in 2022, then grew by 8.46% to $50.1 billion in 2023, then advanced by 8.81% to $54.5 billion in 2024, then advanced by 6.42% to $58.0 billion in 2025, then advanced by 4.84% to $60.8 billion in 2026.
• The last three Non-Current Assets figures came in at $60.8 billion (Q1 2026), $58.0 billion (Q4 2025), and $58.7 billion (Q3 2025), per Business Quant data.